Meridian Wealth Advisors LLC Purchases New Position in Inhibrx, Inc. (NASDAQ:INBX)

Meridian Wealth Advisors LLC acquired a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm acquired 25,000 shares of the company's stock, valued at approximately $385,000. Meridian Wealth Advisors LLC owned 0.17% of Inhibrx as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of INBX. Exchange Traded Concepts LLC purchased a new position in Inhibrx during the 4th quarter valued at about $148,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management bought a new position in Inhibrx in the fourth quarter worth approximately $348,000. China Universal Asset Management Co. Ltd. purchased a new stake in Inhibrx during the fourth quarter worth $47,000. Rhumbline Advisers bought a new stake in Inhibrx during the 4th quarter valued at $228,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Inhibrx in the 4th quarter valued at $53,000. 82.46% of the stock is currently owned by hedge funds and other institutional investors.

Inhibrx Trading Down 3.4 %

NASDAQ:INBX traded down $0.50 during midday trading on Tuesday, reaching $14.22. 83,237 shares of the stock traded hands, compared to its average volume of 214,174. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $35.42. The business has a 50-day moving average of $13.29 and a two-hundred day moving average of $14.62.

Inhibrx (NASDAQ:INBX - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. As a group, sell-side analysts anticipate that Inhibrx, Inc. will post 104.88 earnings per share for the current fiscal year.

Remove Ads

Analysts Set New Price Targets

Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.